Cytokine Release Syndrome and Neurologic Toxicities Associated with Chimeric Antigen Receptor T-Cell Therapy: A Comprehensive Review of Emerging Grading Models

Publication date: Available online 10 June 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Julio C. Chavez, Michael D. Jain, Mohamed A. Kharfan-DabajaAbstractAdvances in the fields of immuno-oncology and T-cell engineering have brought autologous chimeric antigen receptor T-cell (CART) therapies from the bench to the bedside. At present, two CART products that target CD19 are commercially available: tisagenlecleucel and axicabtagene ciloleucel. They have demonstrated remarkable efficacy for their particular indications. One challenge is to compare the safety among commercially available and clinical trial CART treatments due to the use of different grading models to assess the severity of cytokine release syndrome and neurotoxicity. An unmet need exists to harmonize current grading models in order to develop uniform treatment strategies to manage these toxicities. Here, we attempt to summarize the evolution of the various grading systems for cytokine release syndrome and neurotoxicity and also highlight the major differences among them, whenever applicable.
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research